Merck Announces Increased Quarterly Dividend
WHITEHOUSE STATION, N.J. -- November 26, 2013
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today
announced that the Board of Directors has increased the company’s quarterly
dividend to $0.44 per outstanding share of the company’s common stock, up
$0.01 from $0.43 per outstanding share paid last quarter. Payment will be made
on January 8, 2014, to stockholders of record at the close of business on
December 16, 2013.
”This increase in our dividend reflects our focus on creating value for
shareholders and our confidence in Merck’s future as we increase productivity
and invest in our most promising R&D opportunities,” said Kenneth C. Frazier,
chairman and chief executive officer, Merck.
Merck lastannounced a dividend increasein November 2012, when the Board
raised the dividendfrom$0.42to $0.43 percommon share.
Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline products
that the products will receive the necessary regulatory approvals or that they
will prove to be commercially successful. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck patents
and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2012
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
Kelley Dougherty, 908-423-4291
Carol Ferguson, 908-423-4465
Press spacebar to pause and continue. Press esc to stop.